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Information Leaflets: A Cross-Sectional National Survey of 18-
to 65-Year-Olds in England
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Abstract
Introduction Evidence suggests the current verbal risk
descriptors used to communicate side effect risk in patient
information leaflets (PILs) are overestimated.
Objectives The aim was to establish how people understand
the verbal risk descriptors recommended for use in PILs by
the European Commission (EC), and alternative verbal risk
descriptors, in the context of mild and severe side effects.
Methods A cross-sectional online survey was carried out
by a market research company recruiting participants aged
between 18 and 65 years living in England. Data were
collected between 18 March and 1 April 2016. Participants
were given a hypothetical scenario regarding the risk of
mild or severe medication side effects and asked to esti-
mate how many out of 10,000 people would be affected for
each of the verbal risk descriptors being tested.
Results A total of 1003 participants were included in the
final sample. The risks conveyed by the EC recommended
verbal risk descriptors were greatly overestimated by par-
ticipants. Two distinct distributions were apparent for par-
ticipant estimates of side effect risks: those for ‘high risk’
verbal descriptors (e.g. ‘common’, ‘likely’, ‘high chance’)
and those for ‘low risk’ verbal descriptors (e.g. ‘uncommon’,
‘unlikely’, ‘low chance’). Within these two groups, the dis-
tributions were near to identical regardless of what adverb
(e.g. very, high, fair) or adjective (e.g. common, likely,
chance) was used. The EC recommended verbal risk
descriptors were more likely to be understood in accordance
with their intended meanings when describing severe side
effects. Very few demographic or psychological factorswere
consistently associated with how well participants under-
stood the EC recommended verbal risk descriptors.
Discussion The current verbal risk descriptors used in PILs
are ineffective at best and misleading at worst. Discontin-
uing the use of verbal risk descriptors would limit the
likelihood of people overestimating the risk of side effects.
Key Points
This is the first study using a representative sample
to show that people greatly overestimate the intended
frequency of the verbal risk descriptors used to label
side effect risk in patient information leaflets,
especially when describing mild side effects.
Small changes to the wording used in the verbal risk
descriptors will not solve this problem; the issue was
the same for the three different forms of wording that
we tested.
More radical changes (including abandoning the use
of verbal risk descriptors) should be considered.
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1 Introduction
In Europe, all medicines prescribed or sold over-the-
counter must be accompanied by a comprehensive patient
information leaflet (PIL), which is required to present the
risk of potential side effects in ‘clear and understandable
terms for the patient’ [1]. Over 70% of patients receiving
a drug for the first time will read the accompanying PIL
[2].
Effectively communicating information about the risk of
side effects is difficult [3]. In 1998, European Commission
(EC) guidelines suggested grouping adverse effects within
a PIL according to five frequency bands and using a verbal
label for each one [4]. Side effects could be ‘very common’
(experienced by more than one in ten patients), ‘common’
(up to one in ten, ‘uncommon’ (up to one in 100), ‘rare’ (up
to one in 1000), or ‘very rare’ (up to one in 10,000). This
way of quantifying the risk of adverse reactions was
originally suggested by the Council for International
Organizations of Medical Sciences (CIOMS) Working
Group III in 1995 [5], and therefore is also applicable
outside the European Union. Although not based on any
empirical evidence [6], these EC recommended verbal risk
descriptors have become widely used. Of the 50 most
frequently dispensed medicines in England and Wales in
2012, 76% of the PILs used these verbal risk descriptors
[7].
Since the guidelines were published, several studies
have suggested that these verbal risk descriptors are
problematic [8, 9]. It has been shown that UK students
overestimate the risk associated with each of the verbal risk
descriptors [10]. In another UK study, only seven out of
180 participants provided probability estimates for the
verbal risk descriptors ‘common’ and ‘rare’ that fell within
the EU guideline’s frequency range [11]. Studies with
patients have found similar overestimations [12, 13], as has
research with physicians, pharmacists and lawyers [14, 15].
In part, estimations seem to depend on side effect type,
with ‘mild’ side effects given higher estimations than
‘severe’ side effects when described as ‘common’ or ‘rare’
[11].
Since these findings, the guidelines have been updated
and suggest PILs should combine the verbal and numerical
expressions (e.g. ‘very common, more than 1 in 10 people’)
[16]. However, research has shown that this may not lead
to more accurate side effect risk estimates than the verbal
format [17] and still leads to significant risk overestima-
tions when compared with numerical frequency bands
alone [18]. The continued use of the same ‘very common’
to ‘very rare’ wording appears to still present problems for
the public, even despite the addition of numerical
information.
These findings are troubling. If patients systematically
overestimate the risk of side effects from their medications,
this may reduce their adherence and also increase the risk
of symptoms occurring as a result of a nocebo effect [19].
Previous studies have limitations, however, often being
based on small samples that are not representative of the
general population. No study so far has used a national
representative sample. Nor has any study sought to identify
whether there are demographic or psychological factors
that make individuals more or less likely to correctly
estimate the numerical risk represented by these verbal
descriptors. Psychological characteristics such as beliefs
about medicines, optimism or perceived sensitivity to
medicines are associated with medicine side effect expec-
tations [20, 21] and may also affect how people perceive
the risk information about medication.
In this study, we used a large cross-sectional survey of a
representative sample of 18- to 65-year-olds in England in
order to:
1. Assess how people interpret the risk associated with
the EC recommended verbal risk descriptors and two
sets of alternative verbal risk descriptors.
2. Investigate if people interpret the risk associated with
verbal risk descriptors differently depending on
whether they describe a mild or severe side effect.
3. Determine whether demographic or psychological
factors are associated with correctly interpreting the
risk implied by the EC recommended verbal risk
descriptors.
2 Methods
2.1 Design
We commissioned the market research company Ipsos
MORI to conduct an online survey of adults aged between
18 and 65 years living in England. Data collection took
place between 18 March and 1 April 2016. This study was
approved by the Psychiatry, Nursing and Midwifery
Research Ethics Committee at King’s College London
(reference HR-15/16-2104).
The same study was used to assess in detail factors
associated with patients’ expectations of side effects con-
veyed by verbal labels of risk, the results of which have
been submitted elsewhere.
2.2 Participants
Ipsos MORI recruited participants from an existing panel
of people willing to take part in internet surveys living in
England (approximately n = 160,000). We excluded over
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65 s because of a concern that older adults who are
members of an internet survey panel are not representative
of the general population of older adults [22, 23]. Potential
participants were emailed a link to the survey. After pro-
viding informed consent and clicking through to begin the
survey, participants were allocated to receive questions
about either mild or severe side effects. This was decided
by the survey software on the basis of which condition had
the lowest number of completed responses at that time.
Panel participants typically receive points for every survey
they complete; for our survey, participants received points
equivalent to 75 pence.
2.3 Sample Size
Quotas based on participant age and gender (interlocked),
location, and working status were used to ensure that the
sample reflected the known demographic profile of adults
aged 18–65 in England, according to data from the
National Readership Survey [24]. We intended to recruit
1000 participants to provide us with a sample error of about
plus or minus 3% at the total sample level.
2.4 Questionnaire Development
Where possible, we used or adapted items that had been
previously developed and tested for their reliability and
validity. We piloted all items with five members of the
general public and rephrased items where necessary to
improve clarity.
2.5 Primary Outcome: Verbal Risk Descriptor
Probability Estimates
We included several items to assess participant under-
standing of the verbal risk descriptors. These asked people
to consider a PIL for an unnamed drug that stated, for
example, that ‘nausea is common’. Items then asked par-
ticipants to estimate how many out of 10,000 people who
take the drug would develop that side effect. We chose a
consistent denominator for each item to prevent confusion
among participants had denominators changed in each
question. To prevent the need for participants to give
responses of less than one, we decided that a denominator
of 10,000 would be needed. Our choice to get participants
to use numbers is supported by Schwartz and Woloshin
[25], who argue that despite concerns that people do not
understand the use of numbers, representative populations
are competent in using numbers as a decision aid for
choosing between two drugs [26].
Participants were asked about either mild side effects
(‘headache’ or ‘nausea’) or severe side effects (‘seizure’ or
‘difficulty breathing’) depending on which condition they
had been assigned to. We used the EC recommended
verbal risk descriptors ‘very common’, ‘common’, ‘un-
common’, ‘rare’ and ‘very rare’ supplemented with the
terms ‘very uncommon’ and ‘extremely rare’. We also
included other terms used in the risk communication lit-
erature [27–29], which could be combined into similar
scales based on likelihood (very likely, likely, somewhat
unlikely, fairly unlikely, very unlikely, extremely unlikely)
and chance (very high chance, high chance, fair chance,
low chance, very low chance, extremely low chance).
Verbal risk descriptors were presented in a random order to
participants.
2.6 Demographic Factors
We asked participants about their age, gender, ethnicity,
highest level of education, employment status and whether
they or anyone in their household had a long-standing ill-
ness, disability or infirmity.
2.7 Psychological Factors
We adapted the single-item literacy screener [30] assessing
health literacy and asked participants to rate how often they
needed help reading PILs, and included one item that asked
how often they read PILs when taking a new medication.
Both were rated from 1 (‘never’) to 5 (‘always’). We used
one item from the Health Anxiety Inventory [31] to assess
health anxiety, which asked participants to select one of
four statements describing their feelings over the past
6 months. These ranged from 1 ‘I do not worry about my
health’ to 4 ‘I spend most of my time worrying about my
health’.
We assessed optimism using the Revised Life Orienta-
tion Test [32], which consists of six items (plus four filler
items), giving a total score from 5 to 30, with higher scores
indicating higher optimism. Participant beliefs about
medicines were assessed using the overuse and harm
general subscales of the Beliefs about Medicines Ques-
tionnaire (BMQ) [33], providing scores from 5 to 20 for
each subscale, with higher scores indicating higher per-
ceived overuse or harm. Finally, how sensitive participants
thought they were to medicines was assessed using the
Perceived Sensitivity to Medicines scale [34], giving a
score from 5 to 25, with higher scores indicating higher
perceived sensitivity.
2.8 Analysis
We grouped side effect frequency estimates given by par-
ticipants into the same bands as those suggested for use by
the EC guidelines [4] and produced histograms to show the
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frequency with which each band was selected for each
verbal descriptor.
We carried out a series of Mann–Whitney U tests to test
if participants’ median estimates differed between mild and
severe side effects.
We used a series of multinomial logistic regressions to
test if any demographic or psychological characteristics
were associated with participants under-, over- or correctly
estimating the numerical risk associated with the EC rec-
ommended verbal risk descriptors. Participants’ numerical
risk estimates were first recoded as an underestimate,
overestimate or correct estimate for each descriptor. For
the verbal risk descriptors of very common and very rare
(where it is not possible to overestimate or underestimate,
respectively), binary logistic regressions were carried out
instead. For each of the regressions, all demographic
variables and side effect types (mild or severe) were added
to the regression in one block, and each psychological
variable was added on its own, controlling for the previ-
ously entered variables.
For all analyses, answers of ‘don’t know’ or ‘prefer not
to say’ were excluded. A maximum of 3% of participants
answered ‘don’t know’ for any one question where this was
an option, and this was 1% for ‘prefer not to say’. All
analyses were carried out using SPSS 22. Because the
frequency of participants’ side effect numerical estimates
for each of the verbal risk descriptors did not change by
more than 0.2% when using data weighted by age, gender,
region and working status, we used unweighted data for our
analyses.
3 Results
3.1 Sample Characteristics
A total of 1003 participants completed the survey and were
included in the final sample (see Fig. 1 for response rates).
Demographic information for the participants is given in
Table 2.
3.2 People’s Interpretation of the Verbal Risk
Descriptors
Figure 2 shows the frequency of participants’ numerical
risk estimates for each verbal descriptor. Two distinct
distributions were apparent; those for ‘high risk’ verbal
descriptors, which portrayed a side effect as very common,
common, very likely, likely, very high chance, high
chance, or fair chance and those for ‘low risk’ verbal
descriptors, which portrayed a side effect as uncommon,
rare, unlikely and so on. Within these two groups, the
distributions were near to identical regardless of what
adjective (e.g. common, likely, chance) or adverb (e.g.
very, high, fair) was used.
For the ‘high risk’ verbal descriptors, most participants
(84.4% and 81.2%, respectively) thought ‘very common’
and ‘common’ meant a risk of 1001–10,000 per 10,000
patients (i.e. more than one in ten) for mild side effects,
with similar percentages seen for ‘very likely’ (83.8%),
‘likely’ (83.2%), ‘very high chance’ (85.2%), ‘high chance’
(84.0%), and ‘fair chance’ (74.7%). This pattern repeated
itself for severe side effects, with the majority
(56.3–71.2%) of participants giving estimates that corre-
sponded to a risk of 1001–10,000 (more than one in ten).
For ‘low risk’ verbal descriptors, the majority
(61.8–76.7%) of participants provided estimates of
101–1000 (up to one in ten) or 11–100 (up to one in 100)
for mild side effects, with this dropping to 43.5–70.6% for
severe side effects.
3.3 The Effect of the Severity of Side Effects
on People’s Interpretation of the Verbal Risk
Descriptors
Participants’ numerical risk estimates were lower for each
verbal descriptor when it described severe side effects
compared to mild side effects (all p values \0.001, see
Fig. 3).
11,657 people listed as age 
18-65 were emailed the 
study link
1155 clicked on study link
9 dropped out upon reading 
the information sheet
1146 gave consent and 
examined for eligibility
37 were excluded due to 
being identified as 
‘speeding’ or 
‘straightlining’
10,502 did not respond
1144 confirmed eligible 
and started survey
1040 completed the survey
2 dropped out during 
eligibility check
1003 included in the final 
sample
104 dropped out during 
survey
Fig. 1 Participant flow through the survey
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Fig. 2 Participants’ estimates of the meaning for each verbal risk descriptor: a European Commission recommended verbal descriptors; b likely
verbal descriptors; c chance verbal descriptors. *Added in for this study
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3.4 The Association Between Demographic
and Psychological Factors on People’s
Numerical Estimates for the EC Recommended
Verbal Risk Descriptors
The proportions of participants giving correct, over- or
underestimates for the EC recommended verbal risk
descriptors are shown in Table 1. Table 2 shows the
association between demographic and psychological vari-
ables with participants’ numerical estimates. Older partic-
ipants and those from ethnic minorities were generally less
likely to overestimate the numerical risk of the verbal risk
descriptors. Participants with no academic qualifications
were 63% less likely than participants with university
degrees to give correct estimates for ‘very common’, and
56% less likely than participants with degrees to overesti-
mate ‘common’. Participants who had someone in their
household with a long-term illness or disability were 129%
more likely than those without to underestimate ‘rare’. By
far the most influential factor was whether the descriptor
related to mild or severe side effects. In general, mild side
effects were more likely to be overestimated than severe
side effects.
Most psychological characteristics had no association
with whether participants estimated the numerical risk in
accordance with the EC frequency bands. Optimism
showed a small but significant effect for two verbal risk
descriptors, with each 1-point increase in optimism
resulting in participants being 4% less likely to overesti-
mate ‘uncommon’ and 6% less likely to underestimate
‘rare’ descriptors. Belief about the harm of medicines also
showed a small but significant effect for the ‘very com-
mon’ descriptor, with each 1-point increase in harm score
resulting in participants being 6% less likely to give correct
estimates. Finally, for each 1-point increase in health
illiteracy, participants were 24% less likely to provide a
correct estimate for ‘very common’. Similarly, for each
1-point increase in health illiteracy, participants were 27%
less likely to overestimate ‘common’ compared with esti-
mating it in accordance with the EC frequency bands.
3.5 Post-hoc Analyses
As an additional analysis, we tested how much variance
could be explained by entering the predictors altogether in
one model. For predicting correct or incorrect estimates for
the verbal risk descriptors ‘very common’ and ‘very rare’
using binary logistic regression, both models were a good
fit for the data, with both Hosmer and Lemeshow tests
being non-significant (both p values[ 0.068). However,
using Nagelkerke’s R2, the models only explained 10.3% of
the variance in estimates for ‘very common’ and 3.1% of
the variance in estimates for ‘very rare’. Similarly, for
predicting correct, over- or underestimates for the verbal
risk descriptors ‘common’, ‘uncommon’ and ‘rare’ using
multinomial logistic regressions, the models were a good fit
for the data, with all v2 tests being non-significant (all
p values[ 0.232). Again, however, using Nagelkerke’s
R2, the models only explained 12.3% of the variance in
estimates for ‘common’, 10.6% of the variance in estimates
for ‘uncommon’ and 8.7% of the variance for ‘rare’
outcomes.
4 Discussion
4.1 Summary of Main Findings and Interpretation
There are several key findings from our work. First, the
verbal risk descriptors recommended by the EC and com-
monly used in PILs are not accurately interpreted by
members of the public as meaning the same things as the
associated numerical expression. As shown in previous
studies [10, 12, 14, 15], people widely overestimate what
they mean in terms of frequencies. This overestimation of
risk is important, making people less inclined to take their
medication [10, 35] and leading to potentially self-fulfilling
expectations of symptoms [36]. This overestimation gen-
eralises to other verbal risk descriptors not recommended
by the EC; simply tweaking the wording of the verbal risk
descriptors in use seems unlikely to resolve this problem.
Instead, the issue may be a fundamental mismatch between
how we are attempting to communicate (with five different
divisions of frequency) and how people understand risk.
Our data suggest people view verbal risk descriptors as
meaning either ‘likely’ or ‘not likely’—all descriptors are
mentally reinterpreted as one of those two versions.
Second, it is hard to establish who will interpret the risk
information in accordance with the corresponding EC fre-
quency bands. Even combining all our predictors into one
model did little to explain the variance in estimates across
the different verbal risk descriptors. Only age and side
effect type showed a consistent effect. This follows pre-
vious research that has shown that older people have lower
perceptions of risk in general [37]. The finding that mild
side effects were particularly likely to be overestimated has
also been shown previously [11] and may reflect the
influence of the availability of a heuristic [38]; given that
people will have had more experience with headaches than
seizures, it seems likely that people will find it easier to
recall an example of a headache, elevating their perceived
likelihood. Ethnicity, education and health illiteracy did
have an effect, but only for the higher verbal risk
descriptors. White participants, participants with academic
qualifications and those who were more health literate were
more likely to overestimate these high verbal risk
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descriptors. It is possible that white participants are more
likely to overestimate than participants from ethnic
minorities, as it has been shown that they are prescribed
more medications [39] and as such may have more
experience with medication side effects. It is surprising that
participants with academic qualifications and those with
higher health literacy were more likely to overestimate, and
we are unsure why this might be.
Verbal descriptors
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Fig. 3 Median estimates out of 10,000 given for each verbal risk descriptor: a European Commission recommended verbal descriptors; b likely
verbal descriptors; c chance verbal descriptors. *Added in for this study. Bars represent the interquartile range
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4.2 Implications for Side Effect Reporting
Guidelines and Clinical Practice
Verbal risk descriptors have long been favoured for the
presentation of side effect risk on the basis that they can
break up long lists of side effects into more manageable
sections based on frequency and convey the uncertainty of
risk, and because some people are more comfortable with
verbal than numerical information [40]. Current guidelines
suggest PILs should combine the verbal risk descriptors with
the numerical expressions [16]; however, we argue this is not
enough, as it still leads to overestimation [17, 18]. If com-
bined expressions are used, it remains important to use the
correct verbal risk descriptor that is interpreted by people in
the same way as the numerical expression that is associated
with it. However, our survey has shown that verbal risk
descriptors as a whole mislead rather than inform, leading
readers to greatly overestimate their risk of side effects. We
suggest that PILs should abandon the use of these verbal risk
descriptors and instead side effect risk should be grouped
under numerical frequency bands only. As well as having
implications for PILs, the results of this survey also point out
the need for clinical practitioners to reassure patients that
side effects are much less likely than patients think. In
addition, as mild side effects were overestimated more than
severe, we suggest that practitioners may wish to focus in
particular on correcting misperceptions about the likelihood
of mild side effects.
4.3 Strengths and Weaknesses, and Future
Research
This study is strengthened by its large sample size and
the fact that it was demographically representative of 18-
to 65-year-olds in the English population. While it is
possible to question the validity of the data as it is
unknown if online participants read the questions prop-
erly or if they were distracted with other tasks whilst
completing the study [41], this issue may not be as big
as suspected [42], and was partly offset by our exclusion
of participants for ‘straightlining’ or ‘speeding’. It is
limited, however, in terms of selection bias, as we do not
know whether members of market research panels are
psychologically representative of the general population
in terms of attitudes to medicines and their risk of side
effects.
It is possible that the finding that psychological variables
poorly predict participants’ estimates might be due to a
lack of quality in the measures used to capture these
variables. This is unlikely for optimism, belief about
medicines, and perceived sensitivity to medicines, which
were measured using well validated scales; however, health
anxiety, health literacy and PIL reading behaviour were
assessed by modifying validated scales and creating
bespoke items for this study.
The response mode we chose for participants when
estimating the numerical risk of the verbal risk descriptors
also could have affected our results. Participants were
asked to give a number out of 10,000; however, past
research has suggested that open-ended questions such as
this are more susceptible to risk overestimation compared
with questions that require selecting an answer from a few
different response options [43]. We chose this method to
make it easier for participants to express small probabili-
ties, and to allow participants to give their exact thoughts
rather than having to choose from select options covering a
broad range of answers. Nevertheless, we would be inter-
ested in future research to see how the results differ
Table 1 Frequency of how
many people provided
numerical risk estimates for
each EC recommended verbal
risk descriptor that were correct
or incorrect according to the
corresponding EC frequency
bands
Verbal risk descriptor Guess Mild, n (%) Severe, n (%) Total, n (%)
Very common Correct 427 (84.4) 354 (71.2) 781 (77.9)
Incorrect (under) 79 (15.6) 143 (28.8) 222 (22.1)
Common Under 31 (6.1) 82 (16.5) 113 (11.3)
Correct 64 (12.6) 93 (18.7) 157 (15.7)
Over 411 (81.2) 322 (64.8) 733 (73.1)
Uncommon Under 71 (14.0) 125 (25.2) 196 (19.5)
Correct 162 (32.0) 163 (32.8) 325 (32.4)
Over 273 (54.0) 209 (42.1) 482 (48.1)
Rare Under 27 (5.3) 57 (11.5) 84 (8.4)
Correct 86 (17.0) 135 (27.2) 221 (22.0)
Over 393 (77.7) 305 (61.4) 698 (69.6)
Very rare Correct 44 (8.7) 72 (14.5) 116 (11.6)
Incorrect (over) 462 (91.3) 425 (85.5) 887 (88.4)
EC European Commission
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comparing these different types of response options for
estimating the numerical risk of verbal descriptors.
In addition many of the questions used in the survey
were hypothetical, e.g. estimating risk of side effects to an
imagined drug. Future research should replicate this study
with patients given a newly prescribed medication to
remove any limitations relating to the hypothetical sce-
nario used in our survey. We excluded over 65 s because
of concerns about how representative they are in online
surveys. However, over 65 s are the heaviest medication
consumers [44]; therefore, extension of our findings to this
age group would be useful. Research should also examine
whether use of numerical, rather than verbal, descriptors
produce more realistic risk estimates among participants.
As with verbal risk descriptors, different numerical for-
mats are possible (e.g. reframing the risk in terms of the
number/proportion of people who remain side effect free).
Identifying the best way of presenting this information
remains an important goal.
5 Conclusion
Members of the public commonly overestimate the risk
associated with verbal risk descriptors. It may be difficult,
if not impossible, to find the perfect verbal risk descriptors
that are interpreted by the public in line with the different
levels of side effect risk. It may be that PILs should
abandon the use of verbal risk descriptors altogether. This
will limit the opportunity people have to overestimate the
likelihood of side effects, allowing patients to make
informed decisions about their medication and reducing
the occurrence of side effects brought on from negative
expectations, e.g. due to the nocebo effect.
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standards. However, we did not publish the protocol on a publicly
accessible database as it is not industry standard for market research
surveys to be registered in advance.
Informed consent Informed consent was obtained from all individ-
ual participants included in the study.
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